3 September 2026

Release of Securities from Escrow

EVE Health Group Limited (ASX: EVE, EVE or the **Company)** advises that in accordance with ASX Listing Rule 3.10A, that 2,250,000 fully paid ordinary shares will be released from escrow on 9 September 2026.

The shares were issued as consideration under a corporate advisory mandate in May 2026.

Authorised for release by the Company Secretary.

Company enquiries
+61 8 6465 5500
info@evehealthgroup.com.au

About EVE Health Group
EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The Company's lead assets include Dyspro®, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and StiffIssue.com (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.